Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hepatitis C 2Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Liver Diseases 1

Interventions

Sorafenib 4Blood Specimen Collection 4lenvatinib 3sintilimab 2halofantrine 2camrelizumab 2Liver Transplantation 2Antibodies 2trametinib 1toripalimab 1titanium silicide 1tislelizumab 1pembrolizumab 1ledipasvir, sofosbuvir drug combination 1genexol-PM 1gadolinium ethoxybenzyl DTPA 1fluorocholine 1bavituximab 1avatrombopag 1aumolertinib 1atezolizumab 1User-Centered Design 1Sunitinib 1Sufentanil 1Sofosbuvir 1Shadowing Technique, Histology 1Ropivacaine 1Ribavirin 1Radiotherapy 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Liver Diseases × ledipasvir, sofosbuvir drug combination × Clear all
NCT02717949 2019-01-08

Optimal

University of Texas Southwestern Medical Center

Phase 4 Terminated
1 enrolled
Lymphoid

Hepatitis C, Liver Diseases, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡